Crossmark

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study

Crossref DOI link: https://doi.org/10.1186/s40425-018-0461-4

Published Online: 2018-12-05

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Abu-Sbeih, Hamzah

Ali, Faisal S.

Alsaadi, Dana

Jennings, Joseph

Luo, Wenyi

Gong, Zimu

Richards, David M.

Charabaty, Aline

Wang, Yinghong https://orcid.org/0000-0002-5148-6130
License Information

Text and Data Mining valid from 2018-12-01
More Information

Article History

Received: 3 October 2018

Accepted: 20 November 2018

First Online: 5 December 2018

Ethics approval

: The Institutional Review Boards at The University of Texas MD Anderson Cancer Center and Medstar-Georgetown University Center granted a waiver of informed consent for this study.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.